登录  注册

消化病学学术中心

Plecanatide治疗慢性便秘安全有效

Plecanatide safe, effective for chronic constipation

发布者:Frontline Medical News 发布时间:2016-11-18

Two new studies suggest that the peptide plecanatide is safe and effective in the treatment of chronic idiopathic constipation. The drug had a low rate of diarrhea, about 7.1%.

两项最新研究显示,plecanatide用于治疗慢性特发性便秘安全有效,腹泻率较低,约为7.1%。

The research, presented in two posters at the annual meeting of the American College of Gastroenterology, includes a pooled efficacy and safety analysis from two previous phase III clinical trials, as well as an open-label extension study.

在美国胃肠病学会(ACG)年会上,以两张海报的形式报告了这项研究结果,包括来自两项III期临床试验有效性和安全性数据合并分析,以及开放标签延长研究结果。

Though there is no way to be sure in the absence of head-to-head studies, plecanatide could have a better tolerability profile than the existing constipation drugs like lubiprostone (Amitiza) and linaclotide (Linzess).

尽管在缺少头对头研究的情况下难以确认,但plecanatide于耐受性方面可能优于现有的便秘治疗药物,例如鲁比前列酮(Amitiza)和利那洛肽(Linzess)。

“Many patents are still very dissatisfied” with existing drugs, said Satish Rao, MD, PhD, director of the Digestive Health Center at the Medical College of Georgia, Augusta, who presented one of the posters.

佐治亚州大学医学院消化中心主任Satish Rao博士指出:许多患者对现有药物仍非常不满意。

The drug is a derivative of uroguanylin, a peptide found in the gastrointestinal tract. Like the native peptide, plecanatide stimulates digestive fluid movement in the proximal small intestine, which in turn encourages regular bowel function. “I think because it is so much closer to the innate uroguanylin molecule, it will have better tolerability,” said Dr. Rao in an interview.

Plecanatide是存在于消化道中的尿鸟苷素之衍生物。如同天然的肽类,plecanatide刺激近端小肠消化液运动,进而促进正常肠道功能。Rao博士在接受采访时说道:我认为由于该药物与天然尿鸟苷素分子非常相似,因此具有较好的耐受性。

The open-label study followed 2,370 patients who received 3-mg or 6-mg doses of plecanatide once daily for up to 72 weeks. The most common adverse events were diarrhea (7.1%) and urinary tract infection (2.2%), and these were the only adverse events that occurred at a frequency above 2%.

开放标签研究随访了2,370例每日接受3 mg或6 mg plecanatide治疗长达72周的患者。最常见的不良事件包括腹泻(7.1%)和尿路感染(2.2%),这是仅有的发生率超过2%之不良事件。

About 5% of patients discontinued due to adverse events, 3.1% because of diarrhea. Patients were also asked to score their satisfaction with the drug and their willingness to continue on it, and the median values to those answers corresponded to quite satisfied and quite likely to continue.

大约5%的患者因不良事件停止用药,其中3.1%患者是由于腹泻。患者对药物满意度和继续治疗意愿的中位评价结果为非常满意和非常愿意继续治疗。

The other study was a pooled analysis of two previously presented double-blind, placebo-controlled phase III trials of plecanatide. These studies included 2,791 patients with chronic idiopathic constipation who were treated over the course of 12 weeks, with 3- and 6-mg doses. Both groups showed significant improvements in the rate of durable overall complete spontaneous bowel movements: 20.5% in the 3-mg group and 19.8% in the 6-mg group, compared with 11.5% in the placebo group (less than .001 for both comparisons).

另外一项研究是合并分析了此前报告的两项双盲安慰剂对照plecanatide III期试验结果。这两项研究纳入2,791例慢性特发性便秘患者,他们接受为期12周3 mg或6 mg剂量药物治疗。两组患者可耐受的总完全自发性排便率均有显著改善:3 mg和6 mg组分别为20.5%和19.8%,而安慰剂组为11.5%(P<0.001)。

Patients experienced improvements as early as the first week of treatment (31.6% in the 3-mg group versus 16.1% in placebo, P less than .001), and improvements were maintained through the end of the treatment period. There were also significant improvements in secondary endpoints, including stool consistency, straining, and bloating.

患者最早在治疗第一周即可出现症状改善(3 mg组为31.6%,安慰剂组为16.1%,P<0.001),并持续至治疗结束。次要终点指标也得到显著改善,包括大便硬度、排便困难以及腹胀。

Adverse events occurred in 30.6% of subjects taking the 3-mg dose and 31.1% of those taking 6 mg, compared with 28.7% in the placebo group. As with the long-term study, the most common adverse event was diarrhea (4.6% in 3 mg and 5.1% in 6 mg, compared with 1.3% in placebo). Of those in the 3-mg group, 4.1% discontinued, as did 4.5% in the 6-mg group, and 2.2% in the placebo group.

3 mg和6 mg剂量组患者的不良事件发生率分别为30.6%和31.1%,而安慰剂组为28.7%。与长期研究结果相同,最常见的不良事件为腹泻(3 mg和6 mg剂量组分别为4.6%和5.1%,安慰剂组为1.3%)。3 mg和6 mg剂量组患者停药率分别为4.1%和4.5%,安慰剂组为2.2%。

 “I think these are very exciting results. They clearly show a benefit of plecanatide in patients with chronic constipation. These are really methodologically rigorous, large clinical trials that should provide doctors and patients with confidence that the drug will provide benefits,” commented William D. Chey, MD, a professor of medicine at the University of Michigan, Ann Arbor.

密歇根大学安娜堡分校医学教授William D. Chey博士评论指出:我认为这是非常令人兴奋的结果,结果明确显示plecanatide可使慢性便秘患者获益。这些研究方法学严谨的大规模临床试验,能够让医师和患者相信该药物将会给患者带来益处。

Plecanatide is also being developed for irritable bowel syndrome with constipation, and has finished recruitment for two phase III clinical trials, which Synergy expects to report on later this year.

Plecanatide也被开发用于治疗便秘型肠应激综合征,目前已完成两项III期临床试验的入组工作,Synergy公司希望能在今年年底前报告有关结果。

独家授权,未经许可请勿转载!

顶一下(1
来源: Frontline Medical News

发表评论

学科影响因子排名more

 会议回顾 more

  • “2016 消化中外盛举 Best...

  • AASLD The Liver M...

  • 【专题】2015年美国消化疾病周(...

 热门病例 more

 热门指南  more

Elsevier中国网站
爱唯医学网
爱思唯尔科技部
NursingChina
柳叶刀中文版
大通医疗决策
医大爱思唯尔
Elsevier医学数据库
CK
Journal Consult
Procedures_CONSULT
ClinicalPharmacologyLogo
3D Interact Anatomy
Mosby’s Nursing Consult
NursingChina
Science Direct